Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
90Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $3.78B | $392.79M | $5.97 |
| 2024 | $3.58B | $374.54M | $5.65 |
| 2023 | $3.49B | $284.49M | $4.34 |
| 2022 | $3.32B | $239.29M | $3.66 |
| 2021 | $3.23B | $244.10M | $3.72 |
Social Signal Score
Earnings
Thu, Oct 29(in 2 months)
Consensus estimate $1.46 per share
Typical surprise +3.5% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Jul 30$1.42 vs $1.35beat
- Thu, Apr 30$1.19 vs $1.15beat
- Thu, Feb 5$1.25 vs $1.24beat
- Thu, Oct 30$1.62 vs $1.57beat
- Thu, Jul 31$1.66 vs $1.58beat
- Thu, May 1$1.20 vs $1.16beat
Estimates and results for ATR via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
Project earnings forward and see what return today's price implies.
Seeded from ATR's reported EPS growth of 12.6% a year over 4 years.
- EPS in 5 years
- $10.81
- Implied price
- $216.30
- Return from $132.10
- 10.4% a year
To earn 15.0% a year on these assumptions you'd need to buy at $107.54 — -18.6% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 14 | 17 | 20 | 23 | 26 |
|---|---|---|---|---|---|
| 2.6% | -6.4% | -2.7% | 0.6% | 3.4% | 6.0% |
| 7.6% | -1.8% | 2.1% | 5.5% | 8.5% | 11.1% |
| 12.6% | 2.8% | 6.8% | 10.4% | 13.5% | 16.3% |
| 17.6% | 7.3% | 11.6% | 15.3% | 18.5% | 21.5% |
| 22.6% | 11.9% | 16.3% | 20.2% | 23.6% | 26.6% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Mentions (1)
- Newsprnewswire.com·1d ago·Negative
Atrium Therapeutics Reports Second Quarter 2026 Financial Results -- IND clearance for ATR 1072 and launch of Corventis Phase 1/2 trial in PRKAG2 syndrome -- -- Achieved second milestone payment under global cardiovascular collaboration with Bristol Myers Squibb -- SAN DIEGO, Aug. 13, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) ("Atrium," "Atrium Therapeutics," or the "Company"), a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted t…
View source ↗